Beta-blocker therapy in patients with left ventricular systolic dysfunction and chronic obstructive lung disease in an ambulatory care setting

  • Jennifer J. Schimmer
  • Sarah J. Billups
  • Thomas Delate
Keywords: Adrenergic beta-Antagonists, Heart Failure, Pulmonary Disease, Chronic Obstructive, United States

Abstract

Objective: To evaluate beta blocker persistence six months after beta-blocker initiation or dose titration in heart failure (HF) patients with COPD compared to those without COPD. Secondary objectives included comparison of beta-blocker dose achieved, changes in left ventricular ejection fraction (LVEF) and incidence of hospitalizations or emergency department (ED) visits during follow-up.

Methods: We conducted a matched, retrospective, cohort study including 86 patients with COPD plus concomitant HF (LVEF ≤40%) and 137 patients with HF alone. All patients were followed in an outpatient HF clinic. Eligible patients had a documented LVEF ≤40% and were initiated or titrated on a beta-blocker in the HF clinic. Patients were matched based on LVEF (categorized as ≤ 20% or 21-40%), gender, and age (> or ≤70 years). The primary outcome was beta blocker persistence at 6 months. Secondary outcomes were dose achieved, LVEF, and incidence of hospitalizations or ED visits.

Results: There were no differences between the COPD and non-COPD groups in beta-blocker persistence at six-month follow-up (94.2% vs. 93.4% respectively, adjusted p=0.842). The proportion of patients who achieved a daily metoprolol dose equivalent of at least 100 mg was similar between the groups (adjusted p=0.188). The percent of patients with at least one ED visit or hospitalization in the six-month post-titration period was substantial but similar between the groups (53.5% and 48.2% for COPD and non-COPD patients, respectively, adjusted p=0.169).

Conclusion: Our results support the use of beta-blockers in the population of heart failure patients with COPD and without reactive airway disease.

Downloads

Download data is not yet available.

References

1. Writing Committee to update the 2001 Guidelines for the evaluation and management of heart failure chaired by Hunt SA. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: A report of the American College of Cardiology/American Heart Association task force on practice guidelines. American College of Cardiology Web Site available at: http://content.onlinejacc.org/cgi/reprint/46/6/e1.pdf (accessed 19 February 2009).

2. Heart Failure Society of America Writing Committee Co-Chaired by Adams, KF and Lindenfeld J. HFSA 2006 Comprehensive Heart Failure Practice Guideline. J Card Fail. 2006;12:e1-e119. doi:10.1016/j.cardfail.2005.12.001

3. Brophy JM, Joseph L, Rouleau JL. Beta-Blockers in Congestive Heart Failure. A bayesian meta-analysis. Ann Intern Med. 2001;134:550-560.

4. The MERIT-HF Study Group. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the metoprolol CR/XL randomized intervention trial in congestive heart failure (MERIT-HF). JAMA. 2000;283:1295-1337. doi:10.1001/jama.283.10.1295

5. The MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL randomised intervention trial in congestive heart failure (MERIT-HF). Lancet. 1999;353:2001-2007. doi:10.1016/S0140-6736(99)04440-2

6. CIBIS II Investigators and Committees. The cardiac insufficiency bisoprolol study II (CIBIS II): a randomized trial. Lancet. 1999;353:9-13. doi:10.1016/S0140-6736(98)11181-11189

7. Sinha S, Goldstein M, Penrod J, Hochman T, Kamran M, Tenner C, Cohen G, Schwartz MD. Brief report: beta-blocker use among veterans with systolic heart failure. J Gen Intern Med. 2006;21:1306-1309. doi:10.1111/j.1525-1497.2006.00601.x

8. Dart RA, Gollub S, Lazar J, Nair C, Schroeder D, Woolf SH. Treatment of systemic hypertension in patients with pulmonary disease: COPD and asthma. Chest. 2003;123:222-243. doi:10.1378/chest.123.1.222

9. Gheorghiade M, Goldstein S. Beta-blockers in the post-myocardial infarction patient. Circulation .2002;106:394-398. doi:10.1161/01.CIR.0000019582.39797.EF

10. Sirak, TE, Jelic S, LeJemtel TH. Therapeutic update: non-selective beta- and alpha-adrenergic blockade in patients with coexistent chronic obstructive pulmonary disease and chronic heart failure. J Am Coll Cardiol. 2004;44(3):497-502. doi:10.1016/j.jacc.2004.03.063

11. Le Jemtel TH, Padeletti M, Jelic S. Diagnostic and therapeutic challenges in patients with coexistent chronic obstructive pulmonary disease and chronic heart failure. J Am Coll Cardiol. 2007;49;171-180. doi:10.1016/j.jacc.2006.08.046

12. van der Woude HJ, Zaagsma J, Postma DS, Winter TH, van Hulst M, Aalbers R. Detrimental effects of beta-blockers in COPD: a concern for nonselective beta-blockers. Chest. 2005;127:818-824. doi :10.1378/chest.127.3.818

13. Egred M, Shaw S, Mohammad B, Waitt P, Rodrigues E. Under-use of beta-blockers in patients with ischaemic heart disease and concomitant chronic obstructive pulmonary disease. Q J Med. 2005;98:493-497. doi:10.1093/qjmed/hci080

14. Shelton RJ, Rigby AS, Clelan JGF, Clark AL. Effect of a community heart failure clinic on uptake of beta-blockers by patients with obstructive airways disease and heart failure. Heart. 2006;92:331-336. doi:10.1136/hrt.2004.059758

15. Fogari R, Zoppi A, Tettamanti F, Poletti L, Rizzardi G, Fiocchi G. Comparative effects of celiprolol, propranolol, oxprenolol, and atenolol on respiratory function in hypertensive patients with chronic obstructive lung disease. Cardiovasc Drugs Ther. 1990;4:1145-1149. doi:10.1007/BF01856511

16. Mascarenhas J, Lourenco P, Lopes R, Bettencourt P. Chronic obstructive pulmonary disease in heart failure: prevalence, therapeutic and prognostic implications. Am Heart J. 2008;155:521-525. doi:10.1016/j.ahj.2007.10.040

17. Salpeter S, Ormiston t, Salpeter E. Cardioselective beta-blockers for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2005 Oct 19;(4):CD003566. doi:10.1002/14651858.CD003566.pub2

18. Kotlyar E, Keogh AM, Macdonald PS, Arnold RH, McCaffrey DJ, Glanville AR. Tolerability of carvedilol in patients with heart failure and concomitant chronic obstructive pulmonary disease or asthma. J Heart Lung Transplant. 2002;21(12):1290-1295. doi:10.1016/S1053-2498(02)00459-X

19. GOLD Executive and Science Committees. Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2007. Available at: http://www.goldcopd.org/Guidelineitem.asp?l1=2&l2=1&intId=2003 (accessed 19 February 2009).

20. Haley RJ, Licht JH: Metoprolol, atenolol, and propranolol: a comparison at equivalent doses in the treatment of hypertension. Curr Ther Res Clin Exp. 1984;36:993-1003.

21. van der Does R, Hauf-Zachariou U, Pfarr E, Holtbrüugge W, König S, Griffiths M and Lahiri A. Comparison of safety and efficacy of carvedilol and metoprolol in stable angina pectoris. Am J Cardiol. 1999;83:643-649. doi:10.1016/S0002-9149(98)00960-6
Published
2009-12-14
How to Cite
1.
Schimmer JJ, Billups SJ, Delate T. Beta-blocker therapy in patients with left ventricular systolic dysfunction and chronic obstructive lung disease in an ambulatory care setting. Pharm Pract (Granada) [Internet]. 2009Dec.14 [cited 2019Jun.16];7(4):205-12. Available from: https://www.pharmacypractice.org/journal/index.php/pp/article/view/139
Section
Original Research